Try our mobile app

Switch to company model in classical logic    *

General information

Country: IRELAND

Sector: Drug Manufacturers — Specialty and Generic

Perrigo Company PLC is a global healthcare supplier that develops, manufactures, and distributes OTC and generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The Company"s primary markets and locations of manufacturing and logistics operations are the US, UK, Mexico, and Australia.
Website: perrigo.com



Growth: Pretty weak revenue growth rate 5.5%, there is acceleration compared to average historical growth rates -1.3%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +59.0%

Profitability: LTM EBITDA margin is positive, +9.5%. On average the margin is decreasing unsteadily. Gross margin is normal, +33.0%. In the last quarter the company beat the estimated EPS, +7.1%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 3.3%. Free cash flow yield -43.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 25.0% higher than minimum and 33.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.8x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $0.5 mln (0.015% of cap.)

Key Financials (Download financials)

Ticker: PRGO
Share price, USD:  (-0.8%)32.79
year average price 32.38  


year start price 35.74 2023-05-07

max close price 39.94 2023-08-08

min close price 26.23 2024-03-04

current price 32.79 2024-05-05
Common stocks: 134 500 000

Dividend Yield:  3.3%
FCF Yield LTM: -43.0%
EV / LTM EBITDA: 19.1x
EV / EBITDA annualized: 16.4x
Last revenue growth (y/y):  5.5%
Last growth of EBITDA (y/y):  -76.6%
Historical revenue growth:  -1.3%
Historical growth of EBITDA:  9.8%
EV / Sales: 1.8x
Margin (EBITDA LTM / Revenue): 9.5%
Fundamental value created in LTM:
Market Cap ($m): 4 410
Net Debt ($m): 3 609
EV (Enterprise Value): 8 019
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-30Zacks Investment Research

Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect

2024-04-23PRNewsWire

Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024

2024-04-09Seeking Alpha

Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth

2024-02-27Zacks Investment Research

Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View

2024-02-27Zacks Investment Research

Compared to Estimates, Perrigo (PRGO) Q4 Earnings: A Look at Key Metrics

2023-11-15Seeking Alpha

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

2023-11-07Zacks Investment Research

Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View

2023-11-07Market Watch

Perrigo's stock tumbles 14% after sales miss and lowered guidance

2023-08-30Market Watch

FDA warns three baby-formula makers about production violations

2023-08-30Seeking Alpha

The Prognosis For Perrigo
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol PRGO PRGO PRGO PRGO PRGO PRGO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2024-02-27 14:20:57 2023-11-07 12:30:32 2023-08-08 12:05:59 2023-05-09 13:05:11 2023-02-28 15:28:18 2022-11-08 13:48:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 157M 1 124M 1 193M 1 182M 1 155M 1 100M
costOfRevenue 730M 713M 765M 768M 773M 737M
grossProfit 427M 411M 428M 414M 383M 363M
grossProfitRatio 0.369 0.366 0.359 0.350 0.331 0.330
researchAndDevelopmentExpenses 30M 30M 32M 31M 33M 30M
generalAndAdministrativeExpenses 129M 126M 133M 135M 126M 106M
sellingAndMarketingExpenses 178M 178M 200M 197M 182M 175M
sellingGeneralAndAdministrativeExpenses 307M 304M 332M 332M 309M 281M
otherExpenses 800 000 600 000 10M -700 000 100 000 -100 000
operatingExpenses 336M 334M 365M 362M 341M 311M
costAndExpenses 1 066M 1 046M 1 130M 1 130M 1 114M 1 048M
interestIncome 0 52M 50M 0 0 0
interestExpense 43M 44M 44M 44M 41M 41M
depreciationAndAmortization 86M 91M 94M 92M 103M 89M
ebitda 178M 184M 167M 140M 134M 145M
ebitdaratio 0.154 0.164 0.140 0.119 0.116 0.132
operatingIncome -16M 62M 57M 49M 31M 56M
operatingIncomeRatio -0.013 0.055 0.048 0.041 0.027 0.051
totalOtherIncomeExpensesNet -103M -15M 3M -44M -45M -60M
incomeBeforeTax -54M 19M 23M 4M -14M -4M
incomeBeforeTaxRatio -0.047 0.017 0.019 0.004 -0.012 -0.003
incomeTaxExpense -27M 4M 14M 5M -2M 49M
netIncome -32M 14M 8M -1M -13M -52M
netIncomeRatio -0.028 0.013 0.007 -0.001 -0.011 -0.047
eps -0.240 0.110 0.060 -0.008 -0.094 -0.390
epsdiluted -0.240 0.110 0.060 -0.008 -0.094 -0.390
weightedAverageShsOut 136M 136M 137M 135M 135M 135M
weightedAverageShsOutDil 136M 137M 137M 135M 135M 135M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol PRGO PRGO PRGO PRGO PRGO PRGO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2024-02-27 14:20:57 2023-11-07 12:30:32 2023-08-08 12:05:59 2023-05-09 13:05:11 2023-02-28 15:28:18 2022-11-08 13:48:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 751M 598M 555M 553M 601M 469M
shortTermInvestments 100 000 100 000 0 0 0 0
cashAndShortTermInvestments 751M 598M 555M 553M 601M 469M
netReceivables 740M 738M 754M 739M 697M 708M
inventory 1 141M 1 150M 1 168M 1 183M 1 150M 1 085M
otherCurrentAssets 201M 280M 296M 266M 272M 322M
totalCurrentAssets 2 833M 2 765M 2 773M 2 741M 2 720M 2 583M
propertyPlantEquipmentNet 1 100M 1 103M 1 125M 1 131M 1 143M 1 050M
goodwill 3 529M 3 555M 3 658M 3 650M 3 490M 3 492M
intangibleAssets 2 986M 2 941M 3 031M 3 084M 3 289M 3 066M
goodwillAndIntangibleAssets 6 515M 6 496M 6 689M 6 734M 6 779M 6 559M
longTermInvestments 92M 63M 64M 0 0 0
taxAssets 26M 7M 6M 6M 7M 8M
otherNonCurrentAssets 243M 325M 307M 343M 368M 478M
totalNonCurrentAssets 7 976M 7 993M 8 192M 8 214M 8 297M 8 094M
otherAssets 0 0 0 0 0 0
totalAssets 10 809M 10 758M 10 965M 10 955M 11 017M 10 678M
accountPayables 478M 433M 471M 505M 537M 461M
shortTermDebt 441M 38M 38M 39M 36M 34M
taxPayables 42M 10M 8M 18M 14M 22M
deferredRevenue -441M 0 -38M 0 0 8M
otherCurrentLiabilities 1 109M 537M 586M 543M 540M 512M
totalCurrentLiabilities 1 586M 1 008M 1 057M 1 087M 1 114M 1 015M
longTermDebt 3 633M 4 049M 4 056M 4 063M 4 260M 4 078M
deferredRevenueNonCurrent 0 0 0 0 0 409M
deferredTaxLiabilitiesNonCurrent 262M 349M 345M 334M 368M 409M
otherNonCurrentLiabilities 560M 614M 659M 638M 434M 4 557M
totalNonCurrentLiabilities 4 455M 5 012M 5 059M 5 034M 5 062M 5 060M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 173M 173M 180M 185M 190M 0
totalLiabilities 6 041M 6 020M 6 116M 6 121M 6 175M 6 075M
preferredStock 136M 0 0 0 0 0
commonStock 6 838M 6 864M 6 891M 6 911M 6 937M 6 964M
retainedEarnings -2 080M -2 048M -2 062M -2 071M -2 068M -2 044M
accumulatedOtherComprehensiveIncomeLoss 11M -78M 20M -6M -27M -317M
othertotalStockholdersEquity -136M 0 0 0 0 0
totalStockholdersEquity 4 768M 4 738M 4 849M 4 834M 4 842M 4 603M
totalEquity 4 768M 4 738M 4 849M 4 834M 4 842M 4 603M
totalLiabilitiesAndStockholdersEquity 10 809M 10 758M 10 965M 10 955M 11 017M 10 678M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 10 809M 10 758M 10 965M 10 955M 11 017M 10 678M
totalInvestments 92M 63M 64M 0 0 0
totalDebt 4 073M 4 087M 4 094M 4 102M 4 296M 4 111M
netDebt 3 322M 3 488M 3 539M 3 549M 3 695M 3 642M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-07-01 2023-04-01 2022-12-31 2022-10-01
symbol PRGO PRGO PRGO PRGO PRGO PRGO
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2024-02-27 14:20:57 2023-11-07 12:30:32 2023-08-08 12:05:59 2023-05-09 13:05:11 2023-02-28 15:28:18 2022-11-08 13:48:44
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -32M 14M 8M -3M -24M -49M
depreciationAndAmortization 86M 91M 94M 89M 97M 89M
deferredIncomeTax -119M 14M 8M -10M -31M -32M
stockBasedCompensation 11M 15M 19M 25M 8M 9M
changeInWorkingCapital 129M -21M -79M -88M 118M 14M
accountsReceivables 14M 2M -63M -40M 39M 18M
inventory 25M 6M 18M -29M 2M -28M
accountsPayables 27M -24M -39M -30M 54M -18M
otherWorkingCapital 64M -5M 6M 10M 23M 43M
otherNonCashItems 134M 12M 3M 7M 17M 29M
netCashProvidedByOperatingActivities 209M 125M 53M 19M 186M 59M
investmentsInPropertyPlantAndEquipment -27M -32M -20M -23M -26M -21M
acquisitionsNet -2M 200 000 0 0 -110M -1 901M
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 6M 900 000 16M 4M 110M 1 902M
netCashUsedForInvestingActivites -23M -31M -4M -20M -26M -21M
debtRepayment -301M -9M -9M -6M -3M -986M
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid -38M -39M -37M -36M -35M -37M
otherFinancingActivites 294M 5M -3M -9M -4M 980M
netCashUsedProvidedByFinancingActivities -45M -43M -49M -51M -43M -43M
effectOfForexChangesOnCash 12M -7M 2M 3M 15M -12M
netChangeInCash 153M 43M 2M -48M 132M -17M
cashAtEndOfPeriod 751M 598M 555M 553M 601M 469M
cashAtBeginningOfPeriod 598M 555M 553M 601M 469M 485M
operatingCashFlow 209M 125M 53M 19M 186M 59M
capitalExpenditure -27M -32M -20M -23M -26M -21M
freeCashFlow 182M 93M 33M -4M 160M 38M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-27 11:30 ET
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
2024-02-26 21:30 ET
Perrigo Increases its Quarterly Dividend
2024-02-13 13:16 ET
Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024
2023-11-29 13:54 ET
Perrigo Announces Early Results of Cash Tender Offer for Notes
2023-11-10 14:16 ET
Perrigo Announces Cash Tender Offer for Notes
2023-11-07 11:30 ET
Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations
2023-11-02 17:39 ET
Perrigo Announces Quarterly Dividend
2023-10-31 12:54 ET
Perrigo to Attend Upcoming Consumer Investor Conferences
2023-10-24 13:54 ET
Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023
2023-09-11 20:05 ET
Perrigo Announces Leadership Update
2023-08-24 13:41 ET
Perrigo to Attend Upcoming Consumer Investor Conferences
2023-08-08 10:30 ET
Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
2023-08-02 14:19 ET
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
2023-07-25 13:31 ET
Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference
2023-07-13 12:38 ET
Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive
2023-06-08 11:40 ET
Perrigo Appoints Patrick Lockwood-Taylor as President and CEO
2023-05-24 13:09 ET
Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference
2023-05-16 15:43 ET
COUNTRY STAR MITCHELL TENPENNY AND PREVACID ANNOUNCE "BEAT THE BURN" - A LIVE TIK TOK CONCERT TO SING AWAY STRESS
2023-05-16 13:02 ET
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE
2023-05-10 17:40 ET
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
2023-05-09 10:32 ET
Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
2023-05-09 10:30 ET
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
2023-05-04 12:23 ET
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
2023-04-25 13:18 ET
Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023
2023-04-06 12:00 ET
Firefly® Expands Its Commitment to Sustainability with Free Recycling Program
2023-03-28 12:58 ET
Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use
2023-03-02 21:01 ET
Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference
2023-03-01 14:30 ET
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets
2023-02-28 12:44 ET
Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day
2023-02-27 21:58 ET
Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations
2023-02-21 13:28 ET
Perrigo Increases its Quarterly Dividend
2023-02-14 21:04 ET
Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023
2022-12-19 14:00 ET
Perrigo to Host Virtual Investor Day on February 28, 2023
2022-12-16 14:00 ET
SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON
2022-11-08 11:30 ET
Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations
2022-11-03 16:00 ET
Perrigo Announces Quarterly Dividend
2022-11-01 20:01 ET
Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula
2022-10-26 12:30 ET
Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) Use
2022-10-25 21:20 ET
Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022
2022-09-12 13:32 ET
PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE
2022-08-17 20:23 ET
PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY
2022-08-09 10:30 ET
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS
2022-08-02 13:21 ET
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
2022-07-27 12:13 ET
PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022
2022-07-11 10:00 ET
Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill
2022-06-01 12:30 ET
PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER
2022-05-26 13:17 ET
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OMEPRAZOLE MAGNESIUM DELAYED-RELEASE MINI CAPSULES
2022-05-19 12:43 ET
PERRIGO TO PRESENT AT UPCOMING CONSUMER INVESTOR CONFERENCES
2022-05-11 10:32 ET
PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE
2022-05-11 10:21 ET
PERRIGO ANNOUNCES PLANNED LEADERSHIP SUCCESSION
2022-05-05 12:36 ET
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
2022-05-02 11:30 ET
PERRIGO COMPLETES THE ACQUISITION OF HRA PHARMA
2022-04-28 20:39 ET
PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA
2022-04-27 13:03 ET
PERRIGO TO RELEASE FIRST QUARTER 2022 FINANCIAL RESULTS ON MAY 11, 2022
2022-04-20 20:15 ET
PERRIGO ANNOUNCES CLOSING OF $2.6 BILLION SENIOR SECURED CREDIT FACILITIES
2022-04-04 11:30 ET
PERRIGO ANNOUNCES LAUNCH OF PRIVATE NOTES OFFERING
2022-03-28 11:30 ET
PERRIGO ANNOUNCES LAUNCH OF SYNDICATION OF NEW SENIOR SECURED CREDIT FACILITIES
2022-03-24 20:22 ET
PERRIGO ANNOUNCES CFO RETIREMENT AND TRANSITION PLAN
2022-03-17 20:26 ET
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR OTC USE OF NASONEX® 24HR ALLERGY
2022-03-10 13:22 ET
PERRIGO COMPLETES DIVESTITURE OF LATIN AMERICAN BUSINESSES
2022-03-01 12:00 ET
PERRIGO REPORTS FOURTH QUARTER & FISCAL YEAR 2021 FINANCIAL RESULTS FROM CONTINUING OPERATIONS
2022-02-25 13:16 ET
PERRIGO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
2022-02-16 17:30 ET
PERRIGO ANNOUNCES QUARTERLY DIVIDEND
2022-02-15 21:31 ET
PERRIGO TO RELEASE FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ON MARCH 1, 2022
2022-02-03 14:05 ET
Perrigo Expands Occupational Health Program with Premise Health's Digital Wellness Center
2022-01-04 12:59 ET
PERRIGO TO PRESENT VIRTUALLY AT THE 40th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
2021-11-22 13:30 ET
Perrigo Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)
2021-11-10 11:30 ET
Perrigo Reports Third Quarter 2021 Financial Results From Continuing Operations
2021-11-08 13:30 ET
Rolf A. Classon To Not Stand for Re-Election as Chairman of The Perrigo Board of Directors
2021-11-02 15:00 ET
Perrigo Announces Quarterly Dividend
2021-10-27 12:34 ET
Perrigo To Release Third Quarter 2021 Financial Results On November 10, 2021
2021-10-05 20:30 ET
Perrigo Announces New Consumer Self-Care Americas (CSCA) Leadership
2021-09-29 23:32 ET
Perrigo Resolves Irish Tax Assessment for €297 million
2021-09-03 18:21 ET
Perrigo To Host Virtual Investor Meetings At The 2021 Barclays Global Consumer Staples Conference
2021-08-11 10:30 ET
Perrigo Reports Second Quarter 2021 Financial Results From Continuing Operations
2021-08-03 14:39 ET
Perrigo Announces Quarterly Dividend
2021-07-28 13:00 ET
Perrigo To Release Second Quarter 2021 Financial Results On August 11, 2021
2021-07-06 20:33 ET
Perrigo Completes Divestiture Of Generic Rx Business For $1.55 Billion
2021-05-21 12:30 ET
Perrigo To Present Virtually At Upcoming Consumer Investor Conferences
2021-05-18 12:30 ET
Perrigo Divests Latin American Businesses
2021-05-11 10:30 ET
Perrigo Reports First Quarter 2021 Financial Results From Continuing Operations
2021-04-27 20:15 ET
Perrigo To Release First Quarter 2021 Financial Results On May 11, 2021
2021-04-19 14:23 ET
Perrigo Announces Quarterly Dividend
2021-03-01 12:08 ET
Perrigo Reports Fourth Quarter & Fiscal Year 2020 Financial Results
2021-03-01 12:05 ET
Perrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
2021-02-23 17:12 ET
Perrigo Increases Quarterly Dividend By 7%
2021-02-16 13:09 ET
Perrigo To Release Fourth Quarter And Calendar Year 2020 Financial Results On March 1, 2021
2021-01-11 13:00 ET
Perrigo And Michigan State University Announce Partnership To Advance Consumer Self-Care Innovation
2020-12-17 13:03 ET
Perrigo to Present Virtually at Upcoming Investor Conferences
2020-11-17 13:15 ET
Perrigo To Present At The Morgan Stanley Global Consumer & Retail Conference
2020-11-04 21:01 ET
Perrigo Reports Third Quarter 2020 Financial Results
2020-11-04 10:18 ET
Irish High Court Rules Perrigo's Legitimate Expectations Not Violated; Company Remains Committed To Vigorously Challenging The Notice Of Amended Assesment
2020-11-02 22:10 ET
Perrigo Completes Acquisition Of Market-Leading OTC Self-Care Brands In Eastern Europe
2020-11-02 14:46 ET
Travel Safely with Steripod® this Holiday Season
2020-10-29 20:15 ET
Perrigo Updates Earnings Conference Call Timing Scheduled For November 4, 2020, Due To Notification Of Judical Review Decision
2020-10-22 14:37 ET
Perrigo Announces Quarterly Dividend
2020-10-14 12:15 ET
Perrigo To Release Third Quarter 2020 Financial Results On November 4, 2020
2020-09-17 11:29 ET
Perrigo Voluntarily Recalls Albuterol Sulfate Inhalation Aerosol; Reaffirms 2020 Guidance
2020-09-08 14:29 ET
Back-to-School: 4 Ways to Protect from Illness with Steripod®
2020-09-08 13:30 ET
Perrigo Announces The Store Brand Equivalent Of Voltaren® Arthritis Pain Is Available At U.S. Major Retailers Nationwide
2020-08-25 13:52 ET
Perrigo To Present At Upcoming Investor Conferences
2020-08-11 13:29 ET
Perrigo Acquires Market-Leading OTC Self-Care Brands In Eastern Europe
2020-08-05 11:00 ET
Perrigo Company plc Reports Second Quarter 2020 Financial Results
2020-07-29 18:00 ET
Perrigo Announces Quarterly Dividend
2020-07-15 12:32 ET
Perrigo To Release Second Quarter 2020 Financial Results On August 5, 2020
2020-06-19 18:03 ET
Perrigo Announces The Closing Of A Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance Unlimited Company
2020-06-19 12:05 ET
Perrigo Furthers Its Consumer-Focused Transformation By Divesting Its U.K. Generic Prescription Pharmaceuticals Business For £156 Million Or Approximately $195 Million
2020-06-17 12:20 ET
Perrigo Partners With Kazmira LLC To Enter CBD Market Through A Two-Phased, Science-Based Approach
2020-06-16 20:11 ET
Perrigo Announces The Pricing Of A Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance Unlimited Company
2020-06-16 13:10 ET
Perrigo Announces Proposed Public Offering Of Senior Notes Of Its Finance Subsidiary, Perrigo Finance Unlimited Company
2020-06-02 20:14 ET
Perrigo To Present At The 20th Annual Oppenheimer Consumer Growth & E-Commerce Virtual Conference
2020-06-02 13:55 ET
Perrigo Donates 160,000 Toothbrushes to West Michigan Nonprofit Organizations
2020-05-08 18:25 ET
Perrigo To Present At The RBC Capital Markets Global Healthcare Conference
2020-05-05 20:21 ET
Perrigo Announces Quarterly Dividend
2020-05-05 20:08 ET
Perrigo To Present At The Goldman Sachs Global Staples Forum Webcast
2020-04-30 10:30 ET
Perrigo Company plc Reports First Quarter 2020 Financial Results
2020-04-22 20:18 ET
Perrigo Announces Change of Venue and Time of the Annual General Meeting to be Held on Wednesday, May 6, 2020 and Measures to Minimise Any Risk of Coronavirus (COVID-19) Transmission
2020-04-16 12:03 ET
Perrigo to Release First Quarter 2020 Financial Results on April 30, 2020
2020-04-07 20:50 ET
Perrigo Announces Preliminary Unaudited First Quarter 2020 Net Sales And Provides First Quarter Operating Income Range
2020-04-06 12:30 ET
Perrigo Announces FDA Approval for the Store Brand Equivalent of Voltaren® Arthritis Pain
2020-04-02 12:30 ET
Perrigo Completes Acquisition of Oral Care Assets of High Ridge Brands
2020-02-27 11:30 ET
Perrigo Company plc Reports Fourth Quarter & Fiscal Year 2019 Financial Results
2020-02-24 23:57 ET
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-rated Generic Version of ProAir® HFA
2020-02-24 13:59 ET
Perrigo To Acquire Oral Care Assets Of High Ridge Brands
2020-02-18 15:17 ET
Perrigo Increases its Dividend by 7%
2020-02-13 13:30 ET
Perrigo To Release Fourth Quarter And Calendar Year 2019 Financial Results On February 27, 2020
2020-02-07 13:10 ET
Perrigo Announces Consumer Self-Care Americas Segment Leadership Transition
2020-01-14 13:30 ET
Perrigo To Provide Self-Care Transformation Update At J.P. Morgan Healthcare Conference; Announces Robust Preliminary Unaudited Fourth Quarter 2019 Net Sales
2020-01-14 13:30 ET
Perrigo To Provide Self-Care Transformation Update At J.P. Morgan Healthcare Conference; Announces Robust Preliminary Unaudited Fourth Quarter 2019 Net Sales
2020-01-07 18:21 ET
Bernstein Litowitz Achieves Significant Victory Certifying Claims Against Perrigo (NYSE; TASE: PRGO) for Shareholders in Both the United States and Israel
2020-01-06 14:00 ET
Perrigo Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acquisition of Steripod® Toothbrush Accessory Brand
2019-12-02 21:30 ET
Perrigo Announces Closing of Prevacid®24HR (OTC) Acquisition, Advancing Consumer Self-Care Growth Strategy
2019-11-13 14:29 ET
Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference
2019-11-06 11:00 ET
Perrigo Company plc Reports Third Quarter 2019 Financial Results
2019-11-04 14:31 ET
Perrigo Announces Quarterly Dividend
2019-10-23 20:06 ET
Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
2019-03-21 20:05 ET
Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
2019-02-25 12:00 ET
Theralase Announces Appointment of New Chief Executive Officers

SEC forms

Show financial reports only

SEC form 10
2024-02-27 14:20 ET
Perrigo reported for 2023 q4
SEC form 8
2024-02-27 06:40 ET
Perrigo published news for 2023 q4
SEC form 8
2024-02-27 06:40 ET
Perrigo reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Perrigo reported for 2023 q4
SEC form 10
2023-11-07 12:30 ET
Perrigo reported for 2023 q3
SEC form 8
2023-11-07 06:36 ET
Perrigo reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Perrigo reported for 2023 q3
SEC form 6
2023-08-09 16:06 ET
Perrigo published news for 2023 q2
SEC form 10
2023-08-08 12:05 ET
Perrigo reported for 2023 q2
SEC form 6
2023-08-08 06:36 ET
Perrigo reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Perrigo reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Perrigo reported for 2023 q2
SEC form 6
2023-07-12 12:36 ET
Perrigo published news for 2023 q2
SEC form 6
2023-07-10 13:18 ET
Perrigo published news for 2023 q2
SEC form 6
2023-07-10 13:17 ET
Perrigo published news for 2023 q2
SEC form 6
2023-07-07 11:26 ET
Perrigo published news for 2023 q2
SEC form 6
2023-06-20 09:05 ET
Perrigo published news for 2023 q1
SEC form 6
2023-06-14 10:54 ET
Perrigo published news for 2023 q1
SEC form 6
2023-06-09 09:38 ET
Perrigo published news for 2023 q1
SEC form 6
2023-06-08 07:45 ET
Perrigo published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Perrigo reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Perrigo reported for 2023 q1
SEC form 6
2023-03-14 09:38 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-14 09:14 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-09 18:20 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-09 18:09 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:57 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:57 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:57 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:56 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:56 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:56 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:55 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:55 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:55 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-08 16:54 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:38 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:36 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:35 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:33 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:31 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:29 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:28 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 15:24 ET
Perrigo published news for 2022 q4
SEC form 6
2023-03-07 07:48 ET
Perrigo published news for 2022 q4
SEC form 10
2023-02-28 15:28 ET
Perrigo reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Perrigo reported for 2022 q4
SEC form 6
2023-02-27 17:14 ET
Perrigo reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
Perrigo reported for 2022 q4
SEC form 6
2023-02-09 17:00 ET
Perrigo published news for 2022 q4
SEC form 6
2022-12-20 07:51 ET
Perrigo published news for 2022 q3
SEC form 10
2022-11-08 13:48 ET
Perrigo reported for 2022 q3
SEC form 6
2022-11-08 06:38 ET
Perrigo published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Perrigo reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Perrigo reported for 2022 q3
SEC form 6
2022-10-11 15:01 ET
Perrigo published news for 2022 q3
SEC form 6
2022-08-16 16:37 ET
Perrigo published news for 2022 q2
SEC form 10
2022-08-09 15:56 ET
Perrigo reported for 2022 q2
SEC form 6
2022-08-09 06:43 ET
Perrigo published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Perrigo reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Perrigo reported for 2022 q2
SEC form 6
2022-07-15 07:01 ET
Perrigo published news for 2022 q2
SEC form 6
2022-07-14 07:01 ET
Perrigo published news for 2022 q2
SEC form 6
2022-07-12 06:19 ET
Perrigo published news for 2022 q2
SEC form 6
2022-07-11 13:57 ET
Perrigo published news for 2022 q2
SEC form 6
2022-06-22 17:17 ET
Perrigo published news for 2022 q1
SEC form 6
2022-06-09 12:58 ET
Perrigo published news for 2022 q1
SEC form 6
2022-06-09 12:57 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-26 16:09 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-19 13:54 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-19 13:53 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-19 13:53 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-19 13:53 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-19 13:52 ET
Perrigo published news for 2022 q1
SEC form 10
2022-05-11 15:50 ET
Perrigo reported for 2022 q1
SEC form 6
2022-05-11 06:40 ET
Perrigo published news for 2022 q1
SEC form 6
2022-05-11 06:35 ET
Perrigo published news for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Perrigo reported for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Perrigo reported for 2022 q1
SEC form 6
2022-05-02 16:31 ET
Perrigo published news for 2022 q1
SEC form 6
2022-04-28 17:09 ET
Perrigo published news for 2022 q1
SEC form 6
2022-04-20 16:27 ET
Perrigo published news for 2022 q1
SEC form 6
2022-04-07 07:41 ET
Perrigo published news for 2022 q1
SEC form 6
2022-04-04 07:37 ET
Perrigo published news for 2022 q1
SEC form 6
2022-03-28 07:40 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-24 16:31 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-24 08:50 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-16 13:26 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-10 17:01 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:58 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:58 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:57 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:56 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:56 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:56 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:55 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:55 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:54 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-08 16:54 ET
Perrigo published news for 2021 q4
SEC form 10
2022-03-01 14:52 ET
Perrigo published news for 2021 q4
SEC form 6
2022-03-01 07:13 ET
Perrigo published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Perrigo published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Perrigo published news for 2021 q4
SEC form 6
2022-02-11 12:59 ET
Perrigo published news for 2021 q4
SEC form 6
2022-02-09 11:32 ET
Perrigo published news for 2021 q4
SEC form 6
2021-12-20 12:05 ET
Perrigo published news for 2021 q3
SEC form 6
2021-12-17 12:34 ET
Perrigo published news for 2021 q3
SEC form 6
2021-12-09 08:30 ET
Perrigo published news for 2021 q3
SEC form 6
2021-12-07 11:12 ET
Perrigo published news for 2021 q3
SEC form 6
2021-12-06 08:31 ET
Perrigo published news for 2021 q3
SEC form 6
2021-11-22 08:31 ET
Perrigo published news for 2021 q3
SEC form 10
2021-11-12 10:19 ET
Perrigo published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Perrigo published news for 2021 q3
SEC form 6
2021-11-10 06:42 ET
Perrigo published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Perrigo published news for 2021 q3
SEC form 6
2021-11-08 08:31 ET
Perrigo published news for 2021 q3
SEC form 6
2021-10-21 08:00 ET
Perrigo published news for 2021 q3
SEC form 6
2021-10-08 08:01 ET
Perrigo published news for 2021 q3
SEC form 6
2021-09-29 17:29 ET
Perrigo published news for 2021 q2
SEC form 6
2021-09-09 16:05 ET
Perrigo published news for 2021 q2
SEC form 6
2021-09-08 09:48 ET
Perrigo published news for 2021 q2
SEC form 6
2021-08-30 07:02 ET
Perrigo published news for 2021 q2
SEC form 6
2021-08-16 12:02 ET
Perrigo published news for 2021 q2
SEC form 10
2021-08-11 16:25 ET
Perrigo published news for 2021 q2
SEC form 6
2021-08-11 06:50 ET
Perrigo published news for 2021 q2
SEC form 8
2021-08-11 00:00 ET
Perrigo published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
Perrigo published news for 2021 q2
SEC form 6
2021-07-13 16:33 ET
Perrigo published news for 2021 q2
SEC form 6
2021-07-12 16:23 ET
Perrigo published news for 2021 q2
SEC form 6
2021-06-25 12:25 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-19 13:00 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-19 12:59 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-19 12:58 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-19 12:58 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-14 08:39 ET
Perrigo published news for 2021 q1
SEC form 10
2021-05-12 16:59 ET
Perrigo published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-11 14:58 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-11 14:57 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-11 14:56 ET
Perrigo published news for 2021 q1
SEC form 6
2021-05-11 06:38 ET
Perrigo published news for 2021 q1
SEC form 8
2021-05-11 00:00 ET
Perrigo published news for 2021 q1
SEC form 6
2021-04-07 11:46 ET
Perrigo published news for 2021 q1
SEC form 6
2021-04-01 15:23 ET
Perrigo published news for 2021 q1
SEC form 6
2021-03-19 16:05 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-18 14:45 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-11 15:57 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-11 15:57 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:43 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:19 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:19 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:19 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:18 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:18 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:17 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:17 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:17 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:16 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:16 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-09 21:15 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-02 16:32 ET
Perrigo published news for 2020 q4
SEC form 10
2021-03-01 15:52 ET
Perrigo published news for 2020 q4
SEC form 6
2021-03-01 07:21 ET
Perrigo published news for 2020 q4
SEC form 6
2021-02-08 07:27 ET
Perrigo published news for 2020 q4
SEC form 6
2021-02-03 07:12 ET
Perrigo published news for 2020 q4
SEC form 6
2021-01-07 12:31 ET
Perrigo published news for 2020 q4
SEC form 6
2020-12-28 09:02 ET
Perrigo published news for 2020 q3
SEC form 6
2020-12-15 16:11 ET
Perrigo published news for 2020 q3
SEC form 6
2020-11-10 11:48 ET
Perrigo published news for 2020 q3
SEC form 10
2020-11-05 08:17 ET
Perrigo published news for 2020 q3
SEC form 6
2020-11-04 16:10 ET
Perrigo published news for 2020 q3